DongKook Pharmaceutical FY 2025 Annual Report
Beta

Filed: March 12, 2026· period ending December 31, 2025DART

DongKook Pharmaceutical annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 12, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

DongKook Pharmaceutical FY 2025 Annual Report Analysis

Business Overview

• Oral disease treatment tablet sales KRW 45.9B with 56.5% market share in 2024 vs 49.6% in 2023
• Dermatological treatment market share increased to 59.6% in 2024 from 51.1% in 2023

Management Discussion & Analysis

• Revenue KRW 926.9B (+14.1% YoY); Operating profit KRW 9.66B (+20.1% YoY); Net income KRW 7.39B (+18.6% YoY)
• Healthcare segment grew 85% driven by global branding and social media marketing including Instagram and TikTok follower surge

Risk Factors

• No new derivative trades or additional financial instruments signed in FY2025 compared to prior year
• Group-wide risk management policies maintained, with financial risk exposures monitored and reported periodically

DongKook Pharmaceutical FY 2025 Key Financial Metrics
DART

Total Assets

KRW 1.06T

▲ +11.5% YoY

Operating Cash Flow

KRW 68.8B

▼ -9.6% YoY

CapEx

KRW 42.7B

▲ +60.8% YoY

Source: KIFRS consolidated financial data from DongKook Pharmaceutical annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding